The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
 
Milind M. Javle
Consulting or Advisory Role - AstraZeneca; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Sameek Roychowdhury
Stock and Other Ownership Interests - Johnson & Johnson (I)
Consulting or Advisory Role - AbbVie; Incyte; Merck; QED Therapeutics
Research Funding - Ignyta; Incyte; QED Therapeutics; Takeda
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Genentech/Roche; Gilead Sciences; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Saeed Sadeghi
No Relationships to Disclose
 
Teresa Macarulla
Consulting or Advisory Role - Baxalta; Baxter; Celgene; Incyte; Ipsen; Lilly; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Shire
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Merck; Sanofi; SERVIER
 
Dirk Thomas Waldschmidt
No Relationships to Disclose
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Taiho Pharmaceutical
 
Ivan Borbath
Consulting or Advisory Role - Novartis (Inst)
Research Funding - Celgene (Inst); Ipsen (Inst); Novartis (Inst)
 
Anthony B. El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck
 
Wei-Peng Yong
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Bristol-Myers Squibb; Ipsen; Novartis
Speakers' Bureau - Eisai; Lilly; Sanofi/Aventis; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Pfizer
 
Philip Agop Philip
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Michael Bitzer
Consulting or Advisory Role - Bayer/Vital; Bristol-Myers Squibb; Eisai; Ipsen; Lilly
Travel, Accommodations, Expenses - Celgene; Ipsen
 
Suebpong Tanasanvimon
No Relationships to Disclose
 
Ai Li
Employment - QED Therapeutics
Stock and Other Ownership Interests - Bridgebio; QED Therapeutics
 
Amit Pande
Employment - QED Therapeutics
Stock and Other Ownership Interests - Bridgebio; QED Therapeutics
 
Stacie Peacock Shepherd
Employment - Corcept Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Calithera Biosciences; Corcept Therapeutics
Patents, Royalties, Other Intellectual Property - Patents pending for Corcept Therapeutics
 
Susan Moran
Employment - QED Therapeutics
Stock and Other Ownership Interests - Bridgebio; QED Therapeutics
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris